CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe

CSL Behring announced the first real-world use of gene therapy HEMGENIX in treating hemophilia B patients in Europe, offering a one-time treatment to produce Factor IX and reduce bleeding risk. The therapy's approval and accessibility milestone mark a significant advancement in hemophilia treatment.